Iovance Biotherapeutics (IOVA)

• Market cap: $1.52B
• 1 day: 1.19%
• 5 days: -1.45%
• 1 month: -1.45%
• 3 months: 30.27%
• 6 months: 74.36%
• Year to date: 34.92%
• 1 year: 2.1%
• 5 years: -89.29%
• 10 years: -40.04%
• Sector: Healthcare
• Industry: Biotechnology

About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Employees: 975